Calcium channel blocker use and risk of Parkinson's disease: a meta-analysis

Antihypertensive Agents and Risk of Parkinson's Disease: A Nationwide Cohort Study

(2014) Yen-Chieh Lee et al.   PLoS One

Use of Calcium Channel Blockers and Parkinson’s Disease

(2012) Björn Pasternak et al.   AMERICAN JOURNAL OF EPIDEMIOLOGY

Dihydropyridine calcium channel blockers and the progression of parkinsonism

(2011) Connie Marras et al.   ANNALS OF NEUROLOGY

The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease

(2011) E. Ilijic et al.   NEUROBIOLOGY OF DISEASE

Calcium channel blocker use and risk of Parkinson's disease

(2010) Kelly Claire Simon et al.   MOVEMENT DISORDERS

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1

(2010) Jaime N. Guzman et al.   NATURE

Effects of T-type calcium channel blockers on a parkinsonian tremor model in rats

(2010) Hideto Miwa et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Antihypertensive Agents and Risk of Parkinson’s Disease, Essential Tremor and Dementia: A Population-Based Prospective Study (NEDICES)

(2009) Elan D. Louis et al.   NEUROEPIDEMIOLOGY

USE OF ANTIHYPERTENSIVES AND THE RISK OF PARKINSON DISEASE

(2009) A. Ascherio et al.   NEUROLOGY

Incidence and remaining lifetime risk of Parkinson disease in advanced age

(2009) J. A. Driver et al.   NEUROLOGY

Use of antihypertensives and the risk of Parkinson disease

(2008) C. Becker et al.   NEUROLOGY

Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation

(2008) Yachen Li et al.   NEUROPHARMACOLOGY